Resources

HCA – CDS 112bps, Base Case iCDS 65bps, Negative Case iCDS 88bps, 2026 5.875% Bond YTW of 2.411%, iYTW of 1.481%, Ba1 Rating from Moody’s, IG4 (equivalent to Baa2) Rating from Valens, Low Refinancing Need

May 20, 2021

  • CDS markets are slightly overstating credit risk with a CDS of 112bps relative to an Intrinsic CDS of 65bps, while cash bond markets are overstating credit risk with a cash bond YTW of 2.411% relative to an Intrinsic YTW of 1.481%. Meanwhile, Moody’s is overstating HCA’s fundamental credit risk with its Ba1 rating two notches lower than Valens’ IG4 (Baa2) rating
  • Incentives Dictate Behavior™ analysis highlights mostly positive signals for credit holders. HCA’s compensation framework should drive management to focus on top-line growth and margin expansion. Moreover, management members are significant holders of HCA equity relative to their annual compensation, indicating they are likely well-aligned with shareholders for long-term value creation. In addition, management members are not well-compensated in a change-in-control, suggesting they may not be incentivized to accept a takeover or pursue a buyout of the firm, limiting event risk
  • Earnings Call Forensics™ of the firm’s Q1 2021 earnings call (04/22) highlights that management is confident acuity mix, payer mix, and revenue per adjusted admission performance helped their margins significantly. They are also confident they made a large commitment to inpatient rehabilitation facilities in Florida and that capex spending will recover as they repopulate the pipeline with approvals

You don’t have access to the Valens Research Premium Application.

To get access to our best content including the highly regarded Conviction Long List and Market Phase Cycle macro newsletter, please contact our Client Relations Team at 630-841-0683 or email client.relations@valens-research.com.

Please fill out the fields below so that our client relations team can contact you

Or contact our Client Relationship Team at 630-841-0683